Mr. Albini joins Sutro from Itero Biopharmaceuticals, a company focusing on the development and commercialization of protein therapeutics, where he was chief financial officer. Prior to joining Itero, he was chief financial officer at Novacea, where he was responsible for oversight and management of all financial activities, including debt and equity financings, strategic financial evaluation, financial planning and investor relations. Earlier, Mr. Albini was the chief financial officer of Lynx Therapeutics, where he led equity and debt offerings and negotiated revenue-bearing agreements for the company. He worked for more than 14 years in various financial management positions at Genentech, including director of finance for international operations and director of financial planning and analysis. Mr. Albini holds a master’s in business administration from the University of California, Berkeley, and a bachelor’s degree in accounting from Santa Clara University. He is a certified public accountant.
Chief Financial Officer
Shabbir Anik, Ph.D.
Chief Technical Operations Officer
Dr. Shabbir Anik has over 30 years in the pharmaceutical and biotech industry. His expertise spans drug development, pharmaceutical technologies, manufacturing operations, strategic alliances and the contract services business. Shabbir joins us from Onyx/Amgen where he was Senior Vice President, Technical Operations since 2011. Prior to joining Onyx he was the Chief Executive Officer of Althea, a contract manufacturing organization. Previously, he was President, Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon. Shabbir also held leadership positions at Neurex, Oread and Syntex. He received his Ph.D., Pharmaceutical Sciences at the University of Wisconsin, Madison.
VP Human Resources
Linda joined Sutro Biopharma in January 2008 and is a senior advisor in Human Resources and a co-founder of Parallax Venture Partners, an early-stage health care venture fund. Currently, in her role as senior advisor, Linda provides strategic guidance to Sutro BioPharma in the areas of human capital. Prior to her work with Sutro Linda headed the human resources and corporate communications strategy for a variety of publically held biotechnology companies including playing a pivotal role as part of senior management, moderating board compensation committee meetings and serving as an active participant in board of directors meetings. Prior to founding Parallax and her strategic human resources consulting practice, Linda was the Vice President of Human Resources and Corporate Communications at Gilead where she had responsibility for these functions in addition to information technology, facilities and engineering, purchasing and the information center. Linda has also served as Director of Investor Relations and Director of Compensation, Benefits and Systems with Genentech, Inc. In addition, Linda was past Chair of the Biotechnology Innovation Association (BIO) Human Resources committee. Linda graduated with honors from San Francisco State University with a degree in Business, Psychology and Sociology.
Trevor Hallam, Ph.D.
Chief Science Officer
Dr. Hallam brings more than 25 years of experience in drug discovery and development to Sutro. Most recently, he was executive vice president of research & development and executive officer at Palatin Technologies where he was responsible for discovery and clinical development and led the development of several INDs for drug candidates in a variety of therapeutic areas. Prior to joining Sutro, Dr. Hallam held several senior management positions at AstraZeneca, most recently vice president, biologics (respiratory and inflammatory diseases), vice president, U.S. medical affairs, and vice president, preclinical research and development, respiratory and inflammation, Sweden. He began his pharmaceutical career at Smith Kline & French Research, U.K., followed by senior management positions at Glaxo Group Research, U.K., Roche Research Centre, U.K., and Rhone Poulenc Rorer, U.S. Dr. Hallam conducted his post-doctoral training in the laboratory of Timothy J. Rink, M.D., Sc.D., at the Physiological Laboratory, University of Cambridge after receiving his Ph.D. in biochemistry from King’s College, University of London.
VP Technology and Innovation
Mr. Heinsohn has over 24 years of process development and manufacturing experience related to recombinant protein production. He came to Sutro after working at Genentech for 17 years, where he held the role of Senior Scientist and Senior Group Leader for process development, early stage purification activities. While at Genentech, he developed large-scale protein recovery processes, supported research and development activities and participated in regulatory filings for VEGF, thrombopoeitin, Lucentis, and other novel protein therapeutics. He was CMC team leader for the development and launch of Avastin. Prior to joining Genentech, Henry was employed by Genencor International where he was Senior Scientist. Previously, he was a scientist at Corning Medical and Scientific. Henry received a B.S. in Chemistry from North Carolina State University, and conducted postgraduate studies in Biochemistry at the Boston University.
Robert Kiss, Ph.D.
VP Process & Analytical Development
Dr. Robert Kiss has over 26 years of process development and manufacturing experience in the biotechnology industry. Bob came to Sutro after working at Genentech for nearly 24 years, where he most recently held the role of Distinguished Engineer and Senior Director of Late Stage Cell Culture process development. While at Genentech, he was directly involved in the development and initial licensure of the cell culture processes for Rituxan®, Herceptin®, Perjeta®, Tecentriq®, and Ocrevus™, the design and startup of the Vacaville manufacturing sites, and the transfer of multiple cell culture processes to Genentech/Roche and partner sites around the world. He is globally-recognized for expertise in bioprocess scale-up, glycosylation of CHO-derived recombinant proteins, and virus barriers to protect mammalian cell culture processes. He received his chemical engineering degrees from UC Davis (B.S.) and the Massachusetts Institute of Technology (M.S., Ph.D.), is a Fellow in the American Institute of Medical and Biological Engineering, and is a licensed engineer in the state of California.
Mark Lupher, Jr., Ph.D.
VP Translational Pharmacology & Preclinical Development
Dr. Mark Lupher joins Sutro with over twenty years of biomedical research and development experience from discovery through translational clinical development with both biologics and small molecules. He has been an active consultant for Sutro’s preclinical and translational initiatives for over one year. In his earlier position as chief scientific officer of Promedior, Dr. Lupher oversaw several IND applications and early clinical development programs for phase I and phase II clinical trials, as well as Promedior’s drug discovery, preclinical development and intellectual property portfolio. Previously, at ICOS Corporation and Immunex Corporation, he led various drug discovery programs. Dr. Lupher received his Ph.D. in Immunology from Harvard University in Cambridge, MA.
Arturo Molina, M.D., M.S.
FACP, Chief Medical Officer
Dr. Arturo Molina, an oncologist, has led scientific innovation and driven clinical programs forward for over twenty years. With his extensive experience interacting with the FDA and other global regulatory bodies, he has led the development of hematological and oncologic clinical candidates from phase I through phase III and through post-marking trials. He joins Sutro from his former role as VP of oncology and scientific innovation at Johnson & Johnson’s California Innovation Center where he was involved in the evaluation of novel biologics and small molecules, with a focus on immuno-oncology. While working for Johnson & Johnson, Dr. Molina oversaw the approval of Zytiga® in a multitude of countries for metastatic castration resistant prostate cancer indications. Previously, Dr. Molina served as chief medical officer and executive vice-president of Cougar Biotechnology where his leadership efforts advanced the company’s abiraterone program, Zytiga®, from phase I into several global phase III studies. He played a substantial role in the diligence efforts which led to the near $1B acquisition of Cougar by Johnson & Johnson. Dr. Molina has also held leadership positions at Biogen Idec where he led the hematology/oncology clinical development team and oversaw the post-approval label expansion of Rituxan® in front-line follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Dr. Molina was a faculty staff physician and adjunct professor in hematology/bone marrow transplantation and medical oncology/therapeutics research at the City of Hope Comprehensive Cancer Center. Dr. Molina received his M.D. and M.S. degrees from Stanford University School of Medicine in Stanford, CA. He is board certified in internal medicine and medical oncology and has an active California medical license. He additionally has earned distinction as a Fellow of the American College of Physicians.
William J. Newell
Chief Executive Officer
Mr. Newell has over 20 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio, Inc. Mr. Newell is also a Board member on BIO’s Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.
Nicki Vasquez, Ph.D.
SVP Alliance Management/Portfolio Strategy & Operations
Dr. Vasquez brings over 20 years of biopharmaceutical discovery research and development experience to Sutro. Most recently, she was Vice President of Program & Portfolio Management at StemCells, Inc. , where she was responsible for establishing program management for research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.